Cargando…

Tuberculosis Diagnosis and Preventive Monotherapy Among Children and Adolescents Exposed to Rifampicin-Resistant Tuberculosis in the Household

BACKGROUND: Children and adolescents with household exposure to multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) are at high risk of developing TB disease. Tuberculosis preventive therapy (TPT) is recommended, but programmatic experience is limited, particularly for adolescents. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Apolisi, Ivy, Cox, Helen, Tyeku, Nolitha, Daniels, Johnny, Mathee, Shaheed, Cariem, Rabia, Douglas-Jones, Bianca, Ngambu, Noluvo, Mudaly, Vanessa, Mohr-Holland, Erika, Isaakidis, Petros, Pfaff, Colin, Furin, Jennifer, Reuter, Anja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003730/ https://www.ncbi.nlm.nih.gov/pubmed/36910692 http://dx.doi.org/10.1093/ofid/ofad087

Ejemplares similares

Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic
por: Mohr-Holland, Erika, et al.
Publicado: (2021)

Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa
por: Apolisi, Ivy, et al.
Publicado: (2022)

Pediatric delamanid treatment for children with rifampicin-resistant TB
por: Tyeku, N., et al.
Publicado: (2022)

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr-Holland, Erika, et al.
Publicado: (2020)

Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19
por: Mohr-Holland, E., et al.
Publicado: (2021)

Implementing a Substance-Use Screening and Intervention Program for People Living with Rifampicin-Resistant Tuberculosis: Pragmatic Experience from Khayelitsha, South Africa
por: Reuter, Anja, et al.
Publicado: (2022)

Outcomes of Children Born to Pregnant Women With Drug-resistant Tuberculosis Treated With Novel Drugs in Khayelitsha, South Africa: A Report of Five Patients
por: Acquah, Rebecca, et al.
Publicado: (2021)

Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa
por: Mohr, Erika, et al.
Publicado: (2018)

“This is not my body”: Therapeutic experiences and post-treatment health of people with rifampicin-resistant tuberculosis
por: Loveday, Marian, et al.
Publicado: (2021)

Treatment of Infection as a Core Strategy to Prevent Rifampicin-Resistant/Multidrug-Resistant Tuberculosis
por: Reuter, Anja, et al.
Publicado: (2023)

Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study
por: Cox, Helen, et al.
Publicado: (2021)

DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting
por: Mohr, Erika, et al.
Publicado: (2017)

Four months of rifampicin monotherapy for latent tuberculosis infection in children
por: Oh, Chi Eun, et al.
Publicado: (2021)

Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study
por: Cox, Helen, et al.
Publicado: (2022)

“Take the treatment and be brave”: Care experiences of pregnant women with rifampicin-resistant tuberculosis
por: Loveday, Marian, et al.
Publicado: (2020)

Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis
por: Tack, Ilse, et al.
Publicado: (2020)

Early mortality during rifampicin-resistant TB treatment
por: Mohr-Holland, E., et al.
Publicado: (2022)

Direct Observation (DO) for Drug-Resistant Tuberculosis: Do We Really DO?
por: Benbaba, Stella, et al.
Publicado: (2015)

Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa
por: Salaam-Dreyer, Zubeida, et al.
Publicado: (2021)

Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin?
por: Dutta, Noton K., et al.
Publicado: (2015)

Poor Outcomes in a Cohort of HIV-Infected Adolescents Undergoing Treatment for Multidrug-Resistant Tuberculosis in Mumbai, India
por: Isaakidis, Petros, et al.
Publicado: (2013)

Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
por: Zhang, Zehua, et al.
Publicado: (2014)

Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis using machine learning methods
por: You, Shiying, et al.
Publicado: (2022)

Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management
por: Prasad, Rajendra, et al.
Publicado: (2018)

Pyrazinamide resistance in rifampicin discordant tuberculosis
por: Mvelase, Nomonde Ritta, et al.
Publicado: (2022)

Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
por: Cai, Xingshan, et al.
Publicado: (2022)

“A very humiliating illness”: a qualitative study of patient-centered Care for Rifampicin-Resistant Tuberculosis in South Africa
por: Furin, Jennifer, et al.
Publicado: (2020)

Effect of compensatory evolution in the emergence and transmission of rifampicin-resistant Mycobacterium tuberculosis in Cape Town, South Africa: a genomic epidemiology study
por: Goig, Galo A, et al.
Publicado: (2023)

Efficacy and role of Xpert(®) Mycobacterium tuberculosis/rifampicin assay in urinary tuberculosis
por: Samuel, Benedict Paul, et al.
Publicado: (2018)

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
por: Abulfathi, Ahmed A., et al.
Publicado: (2021)

A positive COVID-19 test is associated with high mortality in RR-TB-HIV patients
por: Mohr-Holland, E., et al.
Publicado: (2021)

Rifampicin Resistance in Tuberculosis Outbreak, London, England
por: Jenkins, Claire, et al.
Publicado: (2005)

Rifampicin-induced nephrotoxicity in a tuberculosis patient
por: Beebe, Alexandria, et al.
Publicado: (2015)

Chylothorax in a child with rifampicin-resistant tuberculosis
por: McLaren, B, et al.
Publicado: (2019)

Rifampicin-Mediated Metabolic Changes in Mycobacterium tuberculosis
por: Yelamanchi, Soujanya D., et al.
Publicado: (2022)

Navigating a Path to Rifampicin Resistance in Tuberculosis
por: Agarwal, Sakshi, et al.
Publicado: (2023)

Impact of Decentralized Care and the Xpert MTB/RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South Africa
por: Cox, Helen S., et al.
Publicado: (2015)

Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin‐Treated Pulmonary Tuberculosis
por: Svensson, RJ, et al.
Publicado: (2016)

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre
por: Seijger, Charlotte, et al.
Publicado: (2019)

Interpreting very low Mycobacterium tuberculosis detected on Xpert Mycobacterium tuberculosis/rifampicin
por: Ajbani, Kanchan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_moaji19mvhn0sutsi1i4g9l42d